6 Dimensions Capital
Building 6, Lane 999 Huanke Road, Pudong New District, Shanghai, 201210, China
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Exo Therapeutics | Oct 2021Participated | $78 MSeries B | |
Engine Biosciences | May 2021Participated | $43 MSeries A | |
FogPharma | Mar 2021Participated | $107 MSeries C | |
TScan Therapeutics | Jan 2021Participated | $100 MSeries C | |
Exo Therapeutics | Dec 2020Participated | $25 MSeries A | |
Kira Pharmaceuticals | Nov 2020Participated | $46 MOther Equity | |
ITeos Therapeutics | Apr 2020Participated | $125 MSeries B | |
TScan Therapeutics | Jan 2020Participated | $60 MSeries B | |
Ultivue | Jun 2019Participated | $22 MSeries C | |
NeuSpera Medical | Feb 2019Participated | $12 MSeries B | |
HiberCell | Feb 2019Participated | $61 MSeries A | |
Dewpoint Therapeutics | Jan 2019Participated | $60 MSeries A | |
Exo Therapeutics | Oct 2021Participated | $78 MSeries B | |
Engine Biosciences | May 2021Participated | $43 MSeries A | |
FogPharma | Mar 2021Participated | $107 MSeries C | |
TScan Therapeutics | Jan 2021Participated | $100 MSeries C | |
Exo Therapeutics | Dec 2020Participated | $25 MSeries A | |
Kira Pharmaceuticals | Nov 2020Participated | $46 MOther Equity | |
ITeos Therapeutics | Apr 2020Participated | $125 MSeries B | |
TScan Therapeutics | Jan 2020Participated | $60 MSeries B | |
Ultivue | Jun 2019Participated | $22 MSeries C | |
NeuSpera Medical | Feb 2019Participated | $12 MSeries B | |
HiberCell | Feb 2019Participated | $61 MSeries A | |
Dewpoint Therapeutics | Jan 2019Participated | $60 MSeries A |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 0 |
| Series A | 0 | 5 |
| Series B | 4 | 11 |
| Series C+ | 0 | 6 |
| Other Equity | 0 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Nov '17 | 2 |
| Dec '17 | 0 |
| Jan '18 | 4 |
| Feb '18 | 1 |
| Mar '18 | 4 |
| Apr '18 | 0 |
| May '18 | 3 |
| Jun '18 | 1 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 1 |
| Oct '18 | 0 |
| Nov '18 | 1 |
| Dec '18 | 0 |
| Jan '19 | 1 |
| Feb '19 | 2 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 1 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 1 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 1 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 1 |
| Dec '20 | 1 |
| Jan '21 | 1 |
| Feb '21 | 0 |
| Mar '21 | 1 |
| Apr '21 | 0 |
| May '21 | 1 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 1 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 29 |
| Manufacturing | 2 |
| AI & Machine Learning | 2 |
| Consumer & Lifestyle | 2 |
| Professional Services | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 4 |
| $25M-$50M | 4 |
| $50M-$100M | 12 |
| $100M-$250M | 6 |
| $250M-$500M | 3 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 4 of 4 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 24 |
| Singapore | 2 |
| China | 2 |
| Hong Kong | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| ARCH Venture Partners | 8 |
| Google Ventures | 5 |
| Blue Pool Capital | 4 |
| Boyu Capital | 4 |
| Invus | 4 |
| MPM Capital | 4 |
| Novartis | 4 |
| WuXi AppTec | 4 |
| Bessemer Venture Partners | 3 |
| Casdin Capital | 3 |
| Curative Ventures | 3 |
| Hillhouse Capital | 3 |
| RA Capital Management | 3 |
| WuXi Healthcare Ventures | 3 |
| Action Potential Venture Capital | 2 |
| Alexandria Venture Investments | 2 |
| Applied Ventures | 2 |
| ArrowMark Partners | 2 |
| AVICT Global | 2 |
| Baidu Ventures | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 5 | 17% |
| Participating | 24 | 83% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 2 | 40% |
| Co-led | 3 | 60% |
Team
Managing Partner
Founding Partner & Chairman
Founding Partner
Venture Partner
Managing Partner
Managing Partner and CEO
Executive in Residence